Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life.
Mouth and throat soreness
Oral mucositis
Oral mucositis daily questionnaire
Pain
Patient-reported outcomes
Quality of life
Stem cell transplantation
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
14
02
2022
accepted:
18
04
2022
pubmed:
28
4
2022
medline:
31
5
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Oral mucositis (OM) is one of the most debilitating effects of toxicity due to hematopoietic stem cell transplantation (HSCT) conditioning regimens. The aim of this secondary analysis of the data of a phase II study designed to assess the efficacy of a novel oral care protocol containing bovine colostrum and aloe vera to prevent oral mucositis was to compare outcomes reported by patients with those collected by healthcare professionals (HCPs). Data on oral mucositis severity, duration, time of onset and related pain were collected from patients using the Oral Mucositis Daily Questionnaire (OMDQ). HCPs assessed the same outcomes using the World Health Organization oral mucositis scale and pain numerical rating scale. Quality of life was assessed with the 3-level EuroQol-5 dimensions. Fifty-nine autologous/allogeneic graft patients were recruited, 46 of whom (78.0%) experienced OM. Mean onset was 9.1 (SD ± 3.5) days after conditioning initiation, mean duration was 10.4 (SD ± 4.3) days, and the average maximum pain score was 3.7 (SD ± 2.7). Self-administration of the OMDQ detected oral symptoms at least 1 day sooner compared to objective assessments (p = 0.025). Significant differences were observed between the patient-reported and the HCP-assessment data on oral mucositis severity grading distribution (p < 0.0001) and highest pain score (p < 0.0001). Quality of life score variations were correlated with changes in oral mucositis severity during patients' hospital stay. Further studies are necessary to improve the understanding of these findings; a randomised controlled trial is being set up at our institution.
Sections du résumé
BACKGROUND
BACKGROUND
Oral mucositis (OM) is one of the most debilitating effects of toxicity due to hematopoietic stem cell transplantation (HSCT) conditioning regimens. The aim of this secondary analysis of the data of a phase II study designed to assess the efficacy of a novel oral care protocol containing bovine colostrum and aloe vera to prevent oral mucositis was to compare outcomes reported by patients with those collected by healthcare professionals (HCPs).
METHOD
METHODS
Data on oral mucositis severity, duration, time of onset and related pain were collected from patients using the Oral Mucositis Daily Questionnaire (OMDQ). HCPs assessed the same outcomes using the World Health Organization oral mucositis scale and pain numerical rating scale. Quality of life was assessed with the 3-level EuroQol-5 dimensions.
RESULTS
RESULTS
Fifty-nine autologous/allogeneic graft patients were recruited, 46 of whom (78.0%) experienced OM. Mean onset was 9.1 (SD ± 3.5) days after conditioning initiation, mean duration was 10.4 (SD ± 4.3) days, and the average maximum pain score was 3.7 (SD ± 2.7). Self-administration of the OMDQ detected oral symptoms at least 1 day sooner compared to objective assessments (p = 0.025). Significant differences were observed between the patient-reported and the HCP-assessment data on oral mucositis severity grading distribution (p < 0.0001) and highest pain score (p < 0.0001). Quality of life score variations were correlated with changes in oral mucositis severity during patients' hospital stay.
CONCLUSIONS
CONCLUSIONS
Further studies are necessary to improve the understanding of these findings; a randomised controlled trial is being set up at our institution.
Identifiants
pubmed: 35474550
doi: 10.1007/s00520-022-07073-8
pii: 10.1007/s00520-022-07073-8
pmc: PMC9135813
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6317-6325Informations de copyright
© 2022. The Author(s).
Références
Granot N, Storb R (2020) History of hematopoietic cell transplantation: challenges and progress. Haematologica 105(12):2716–2729. https://doi.org/10.3324/haematol.2019.245688
doi: 10.3324/haematol.2019.245688
pubmed: 33054108
pmcid: 7716373
Zulu S, Kenyon M, Principles of conditioning therapy and cell infusion (2017) 22. In: Kenyon M, Babic A (eds) The European blood and marrow transplantation textbook for nurses: under the auspices of EBMT. Springer, Cham (CH), p 2018
Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813–1826. https://doi.org/10.1056/NEJMra052638
doi: 10.1056/NEJMra052638
pubmed: 16641398
Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V et al (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study. Bone Marrow Transplant 46(5):727–732. https://doi.org/10.1038/bmt.2010.184
doi: 10.1038/bmt.2010.184
pubmed: 20818449
Filicko J, Lazarus HM, Flomenberg N (2003) Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 31(1):1–10. https://doi.org/10.1038/sj.bmt.1703776
doi: 10.1038/sj.bmt.1703776
pubmed: 12621500
Chaudhry HM, Bruce AJ, Wolf RC et al (2016) The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant 22(4):605–616
doi: 10.1016/j.bbmt.2015.09.014
Bachour PC, Sonis ST (2018) Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. Curr Opin Support Palliat Care 12(2):198–210
doi: 10.1097/SPC.0000000000000339
Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45(12):1015–1020
doi: 10.1016/j.oraloncology.2009.08.006
Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. 2002 More than a sore mouth: patients’ experience of oral mucositis. In: Oncol Nurs Forum. Vol 29
Rodrigues-Oliveira L, Kowalski LP, Santos M et al (2021) Direct costs associated with the management of mucositis: a systematic review. Oral Oncol 118:105296
doi: 10.1016/j.oraloncology.2021.105296
Bezinelli LM, Eduardo FP, Neves VD, Correa L, Lopes RM, Michel-Crosato E, Hamerschlak N, Biazevic MG (2016) Quality of life related to oral mucositis of patients undergoing haematopoietic stem cell transplantation and receiving specialised oral care with low-level laser therapy: a prospective observational study. Eur J Cancer Care (Engl) 25(4):668–674
doi: 10.1111/ecc.12344
Miranda-Silva W, Gomes-Silva W, Zadik Y et al (2021) MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. Support Care Cancer 29(7):3539–3562
doi: 10.1007/s00520-020-05803-4
Mawardi H, Treister N, Felemban O et al (2021) Current practice of oral care for hematopoietic stem cell transplant patients: a survey of the Eastern Mediterranean Blood and Marrow transplantation group. Published online, Hematology/Oncology and Stem Cell Therapy
Rathe M, De Pietri S, Wehner PS et al (2020) Bovine colostrum against chemotherapy-induced gastrointestinal toxicity in children with acute lymphoblastic leukaemia: a randomized, double-blind, placebo-controlled trial. J Parenter Enter Nutr 44(2):337–347
doi: 10.1002/jpen.1528
da LimaSilva ICG, deFátimaSoutoMaior L, Gueiros LAM, Leão JC, Higino JS, Carvalho AAT (2021) Clinical applicability of natural products for prevention and treatment of oral mucositis: a systematic review and meta-analysis. Clin Oral Investig 25(6):4115–4124. https://doi.org/10.1007/s00784-020-03743-1
doi: 10.1007/s00784-020-03743-1
Yarom N, Hovan A, Bossi P, et al. 2020 Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines—part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Support Care Cancer Published online 1–16.
Gok Metin Z, Helvaci A, Gulbahar EM (2021) Effects of aloe vera in adults with mucocutaneous problems: a systematic review and meta-analysis. J Adv Nurs 77(3):1105–1126
doi: 10.1111/jan.14653
Guberti M, Botti S, Capuzzo MT et al (2021) Bovine colostrum applications in sick and healthy people: a systematic review. Nutrients 13(7):2194
doi: 10.3390/nu13072194
Salehi B, Lopez-Jornet P, Pons-Fuster López E et al (2019) Plant-derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, aloe vera, green tea and coffee properties. Biomolecules 9(3):106
doi: 10.3390/biom9030106
Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8(1):33–39. https://doi.org/10.1007/s005209900095
doi: 10.1007/s005209900095
pubmed: 10650895
Quinn B, Potting CM, Stone R, Blijlevens NM, Fliedner M, Margulies A, Sharp L (2008) Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer 44(1):61–72. https://doi.org/10.1016/j.ejca.2007.09.014
doi: 10.1016/j.ejca.2007.09.014
pubmed: 17988858
Bateman E, Keefe D (2011) Patient-reported outcomes in supportive care. Semin Oncol 38(3):358–361
doi: 10.1053/j.seminoncol.2011.03.003
Stiff PJ, Emmanouilides C, Bensinger WI et al (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24(33):5186–5193
doi: 10.1200/JCO.2005.02.8340
Stiff PJ, Erder H, Bensinger W et al (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37(4):393–401
doi: 10.1038/sj.bmt.1705250
Cheng KK, Lee V, Li CH, Yuen HL, Epstein JB (2012) Oral mucositis in pediatric and adolescent patients undergoing chemotherapy: the impact of symptoms on quality of life. Support Care Cancer 20(10):2335–2342. https://doi.org/10.1007/s00520-011-1343-1
doi: 10.1007/s00520-011-1343-1
pubmed: 22167295
Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Yamamoto S, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N (2012) Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer 20(2):367–373. https://doi.org/10.1007/s00520-011-1116-x
doi: 10.1007/s00520-011-1116-x
pubmed: 21328006
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010). Bone Marrow Transplant 56, 336–343 (2021). doi: https://doi.org/10.1038/s41409-021-01344-4 .
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10
doi: 10.1016/0197-2456(89)90015-9
Syrjala K, Hays RD, Kallich JD et al (2003) Impact of oral mucositis and its sequelae on quality of life. Blood 102:751a
Tardieu C, Cowen D, Thirion X, Franquin JC (1996) Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer B Oral Oncol 32B(6):381–387. https://doi.org/10.1016/s0964-1955(96)00026-7
doi: 10.1016/s0964-1955(96)00026-7
pubmed: 9039221
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337–343. https://doi.org/10.3109/07853890109002087
doi: 10.3109/07853890109002087
pubmed: 11491192
EuroQol Research Foundation. EQ-5D-3L User Guide, 2018. Available from: https://euroqol.org/publications/user-guides . Accessed: January 10, 2022.
Scalone L, Cortesi PA, Ciampichini R, Belisari A, D’Angiolella LS, Cesana G, Mantovani LG. Italian population-based values of EQ-5D health states. Value Health. 2013 Jul-Aug;16(5):814–22. doi: https://doi.org/10.1016/j.jval.2013.04.008 .
Basch E, Torda P, Adams K (2013) Standards for patient-reported outcome-based performance measures. JAMA 310(2):139–140. https://doi.org/10.1001/jama.2013.6855
doi: 10.1001/jama.2013.6855
pubmed: 23839744
Ní Ríordáin R, Shirlaw P, Alajbeg I, Al Zamel GY, Fung PL, Yuan AD, McCreary C, Stoopler ET, De Rossi SS, Lodi G, Greenberg MS, Brennan MT (2015) World Workshop on Oral Medicine VI: patient-reported outcome measures and oral mucosal disease: current status and future direction. Oral Surg Oral Med Oral Pathol Oral Radiol 120(2):152–60.e11. https://doi.org/10.1016/j.oooo.2015.01.023
doi: 10.1016/j.oooo.2015.01.023
pubmed: 25934415
Bowling A (1995) Measuring disease: a review of disease specific quality of life measurement scales. Open University Press, Buckingham, UK
Black N, Jenkinson C (2009) Measuring patients’ experiences and outcomes. BMJ 2(339):b2495. https://doi.org/10.1136/bmj.b2495
doi: 10.1136/bmj.b2495
Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, Horowitz MM, Martin PJ, McGuire DB, Mullane K, Oster G (2002) Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest 20(5–6):793–800. https://doi.org/10.1081/cnv-120002497
doi: 10.1081/cnv-120002497
pubmed: 12197238
Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17(2):179–193. https://doi.org/10.1007/s11136-007-9295-0
doi: 10.1007/s11136-007-9295-0
pubmed: 18175207
Marshall S, Haywood K, Fitzpatrick R (2006) Impact of patient-reported outcome measures on routine practice: a structured review. J Eval Clin Pract 12(5):559–568. https://doi.org/10.1111/j.1365-2753.2006.00650.x
doi: 10.1111/j.1365-2753.2006.00650.x
pubmed: 16987118
Alvarado Y, Bellm LA, Giles FJ (2002) Oral mucositis: time for more studies. Hematology 7(5):281–289. https://doi.org/10.1080/1024533021000037216
doi: 10.1080/1024533021000037216
pubmed: 12850815
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590–2598. https://doi.org/10.1056/NEJMoa040125
doi: 10.1056/NEJMoa040125
pubmed: 15602019
Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4(4):277–284. https://doi.org/10.1038/nrc1318
doi: 10.1038/nrc1318
pubmed: 15057287
Al-Rudayni A, Gopinath D, Maharajan M, Menon R (2020) Impact of oral mucositis on quality of life in patients undergoing oncological treatment: a systematic review. Transl Cancer Res 9(4):3126–3134. https://doi.org/10.21037/tcr.2020.02.77
doi: 10.21037/tcr.2020.02.77
pubmed: 35117676
pmcid: 8797334
Kamulegeya A, Nakanjako D, Orem J, Mayanja-Kizza H (2021) Experiences of patients who developed oral mucositis during solid neoplasms treatment: a Ugandan qualitative study. J Patient Rep Outcomes 5(1):24. https://doi.org/10.1186/s41687-021-00301-5
doi: 10.1186/s41687-021-00301-5
pubmed: 33677726
pmcid: 7937001